547P - Focused analysis of major known fusion mutations in East Asian non-small cell lung cancers

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Biomarkers
Thoracic Malignancies
Translational Research
Presenter Han-Lin Hsu
Citation Annals of Oncology (2016) 27 (suppl_9): ix177-ix178. 10.1093/annonc/mdw600
Authors H. Hsu1, G. Hsiao1, E. Liu2
  • 1Graduate Institute Of Medical Sciences, College Of Medicine, Taipei Medical Unversity, 11031 - Taipei/TW
  • 2Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Wan Fang Hospital, Taipei Medical University, 116 - Taipei/TW



The major known fusion mutations of ALK, ROS1, RET and NTRK1) are identified as targetable genetic aberrations in non-small cell lung cancer (NSCLC). Their features are not clearly in East Asia populations. This study aimed to examine clinical characteristics of the major fusion mutations in NSCLC patients from East Asia.


We examined the prevalence of ALK, ROS1, RET, and NTRK1 fusion genes in 149 NSCLC patients using barcoded magnetic beaded (BMB) multiplex assays and confirmed the mutations by Sanger sequencing. We also correlated their mutation status, histology, clinical features and outcomes in these patients.


Of 149 patients with NSCLC, 12 (8.1%) had fusion genes, including four (2.7%) with ALK fusion; 4 (2.7%) with ROS1 fusion; 4 (2.7%) with RET fusion. But none had NTRK1 fusion. Among them, the overall prevalence of ALK, ROS1 and RET fusion genes was 18.5% (12/65) in wild-type EGFR non-squamous cell lung cancer patients. There was no statistically significant difference in age, sex, stages, performance status between groups. Patients with ALK or ROS1 fusion tend to be younger and never smokers. By contrast, patients with RET fusion tend to be older (>65 years old), and smokers. Compared with those with EGFR, ALK or ROS1 mutations, significantly shorter survival was observed in patients with RET fusion (HR 7.079, p 


We have detected fusion mutations in NSCLCs using BMB multiplex assay. As higher percentage of fusion mutations was found in wild-type EGFR non-squamous cell lung cancer patients, extensive molecular testing for fusion mutations should be implanted in those patients to achieve the goal of personalized medicine.

Clinical trial indentification


Legal entity responsible for the study

Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan


Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Grant number 102 wf-phd-05


All authors have declared no conflicts of interest.